药品经营使用环节减免违法责任处罚适用情形

摘 要 通过陈述现行法律法规中无过错责任界定的法理依据、分析药品经营、使用环节中减免责条款使用现状，明确药品经营企业、使用单位的责任范围，同时明确梳理出其可以依法予以免责或者减轻处罚的具体情形，探索新《中华人民共和国药品管理法》施行中具有可操作性的细则，为药品事中事后监管积极探索可行性方案。

关键词 无过错责任 药品经营使用环节 减免责条款 事中事后监管

中图分类号：R951 文献标志码：C 文章编号：1006-1533（2022）09-0047-03

引用本文 谭云. 药品经营使用环节减免违法责任处罚适用情形[J]. 上海医药， 2022， 43（9）： 47-49； 57.

Circumstances of application of the reduction or exemption of penalties for illegal liability in the process of drug distribution and usage

TAN Yun

（Shanghai Pharmaceutical Co.， Ltd.， Shanghai 200032， China）

ABSTRACT By stating the legal basis for the definition of the no-fault liability in current laws and regulations， analyzing the current situation of the use of the exemption clause in the process of drug distribution and usage， the scope of responsibility of drug trading enterprises and user units is clarified. According to the law， the specific circumstances in which they can be exempted from liability or mitigated punishment are sorted out. Moreover， the operable rules in the implementation of the new Drug Administration Law are explored to figure out a feasible scheme for the supervision of drugs during and after the event.

KEY WORDS no-fault liability； the process of drug distribution and usage； reducing and immunity from legal liability； supervision of drugs during and after the event

新版《中华人民共和国药品管理法》[1]（以下简称《药品管理法》）已于2019年12月1日起施行，对假劣药条款做了大幅修订。（剩余5626字）